BioPontis, J&J deal

Johnson & Johnson's Janssen Biotech Inc. subsidiary will provide guidance on BioPontis' early science and development programs in-licensed from its university partners to help ensure that BioPontis' programs align with market demand. Janssen will also evaluate and have opportunities to license "early-stage therapeutic opportunities." Terms were not disclosed. ...